Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant Proteins

Patent No. EP2970980 (titled "Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant Proteins") was filed by Janssen Biologics on Mar 7, 2014. The application was issued on Jul 27, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
CABINET LAVOIXMay 15, 2019LAVOIX

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2970980

JANSSEN BIOLOGICS
Application Number
EP14768761A
Filing Date
Mar 7, 2014
Status
Patent Maintained As Amended
Jun 24, 2022
Publication Date
Jul 27, 2022